Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR043727, R01 AR069572)
Biogen Idec (NA)
Received: 2 August 2018
Accepted: 26 December 2018
First Online: 9 January 2019
Ethics approval and consent to participate
: The study protocol for SPARE (Study of biological Pathways, disease Activity and REsponse markers in patients with systemic lupus Erythematosus) was approved by the Johns Hopkins University School of Medicine Institutional Review Board. All patients provided written informed consent.
: Not applicable.
: NA and PC are employees of and stockholders in Biogen.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.